Analysis of Reportable Segments
IQVIA Holdings Inc. operates in 3 segments: Technology & Analytics Solutions; Research & Development Solutions; and Contract Sales & Medical Solutions.
Segment Profit Margin
IQVIA Holdings Inc., profit margin by reportable segment
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Technology & Analytics Solutions | 26.98% | 26.35% | 25.03% | 24.54% | 24.73% |
| Research & Development Solutions | 21.40% | 19.53% | 18.19% | 19.71% | 20.64% |
| Contract Sales & Medical Solutions | 5.65% | 9.57% | 7.69% | 6.39% | 7.28% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The segment profit margins exhibit divergent trends across the three business units from 2018 to 2022, characterized by steady expansion in technology-driven services, a cyclical recovery in research solutions, and significant volatility in medical solutions.
- Technology & Analytics Solutions
- This segment demonstrates the highest and most consistent profitability. After a marginal decline in 2019, profit margins entered a period of sustained growth, increasing from 24.54% to 26.98% by the end of 2022. This trajectory indicates strong operational leverage and a stable cost structure relative to revenue growth.
- Research & Development Solutions
- Profitability in this segment followed a U-shaped pattern over the five-year period. A contraction occurred between 2018 and 2020, with margins dipping from 20.64% to a low of 18.19%. However, a subsequent recovery was observed, with margins expanding to 21.40% in 2022, surpassing the initial 2018 levels.
- Contract Sales & Medical Solutions
- This segment maintains the lowest profit margins and exhibits the highest degree of instability. Margins fluctuated between a peak of 9.57% in 2021 and a five-year low of 5.65% in 2022. The sharp decline in the final year suggests increased operational costs or pricing pressures specifically impacting this business unit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment Profit Margin: Technology & Analytics Solutions
IQVIA Holdings Inc.; Technology & Analytics Solutions; segment profit margin calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Segment profit | 1,550) | 1,458) | 1,216) | 1,101) | 1,023) |
| Revenues | 5,746) | 5,534) | 4,858) | 4,486) | 4,137) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 26.98% | 26.35% | 25.03% | 24.54% | 24.73% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment profit margin = 100 × Segment profit ÷ Revenues
= 100 × 1,550 ÷ 5,746 = 26.98%
The Technology & Analytics Solutions segment demonstrates a consistent upward trajectory in both scale and profitability over the five-year period ending December 31, 2022. Total revenues and segment profits grew steadily, with a notable acceleration in growth rates during the 2021 fiscal year.
- Revenue Expansion
- Revenues increased from US$ 4,137 million in 2018 to US$ 5,746 million in 2022. This growth was characterized by a significant surge in 2021, where revenues rose by approximately 13.9% compared to the previous year, before moderating to a 3.8% increase in 2022.
- Segment Profit Performance
- Segment profit grew from US$ 1,023 million in 2018 to US$ 1,550 million in 2022. The most substantial increase occurred between 2020 and 2021, with profits rising from US$ 1,216 million to US$ 1,458 million, indicating strong earnings momentum during this period.
- Profit Margin Analysis
- The segment profit margin exhibited overall expansion, moving from 24.73% in 2018 to 26.98% in 2022. While a marginal contraction occurred in 2019 (24.54%), the margin improved consistently from 2020 onwards. The increase from 25.03% in 2020 to nearly 27% by 2022 suggests improved operational leverage and cost management as the segment scaled.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment Profit Margin: Research & Development Solutions
IQVIA Holdings Inc.; Research & Development Solutions; segment profit margin calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Segment profit | 1,695) | 1,476) | 1,048) | 1,141) | 1,128) |
| Revenues | 7,921) | 7,556) | 5,760) | 5,788) | 5,465) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 21.40% | 19.53% | 18.19% | 19.71% | 20.64% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment profit margin = 100 × Segment profit ÷ Revenues
= 100 × 1,695 ÷ 7,921 = 21.40%
The Research & Development Solutions segment experienced a U-shaped trajectory in profit margins between 2018 and 2022, characterized by an initial period of contraction followed by a significant recovery and expansion. While the segment maintained a baseline of profitability, the relationship between revenue growth and profit margin shifted notably after 2020.
- Revenue Growth Trends
- Revenues showed moderate growth between 2018 and 2020, remaining relatively stagnant at approximately 5.7 billion US dollars. However, a substantial acceleration occurred starting in 2021, with revenues jumping to 7.56 billion US dollars and further increasing to 7.92 billion US dollars by 2022. This represents a significant expansion of the segment's scale over the five-year period.
- Profitability and Margin Fluctuations
- Segment profit margins declined steadily from 20.64% in 2018 to a low of 18.19% in 2020, coinciding with a slight dip in absolute segment profit to 1.05 billion US dollars. This downward trend was reversed in 2021, as margins rose to 19.53% and subsequently reached a period peak of 21.40% in 2022. The absolute segment profit grew aggressively in the final two years, reaching 1.70 billion US dollars by the end of 2022.
- Operational Efficiency and Scaling
- The data indicates a strong positive correlation between increased revenue volume and margin expansion in the latter part of the observed period. The ability to increase the profit margin to 21.40% while simultaneously growing revenues suggests the realization of economies of scale or an improvement in the pricing power and operational efficiency of the Research & Development Solutions segment.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment Profit Margin: Contract Sales & Medical Solutions
IQVIA Holdings Inc.; Contract Sales & Medical Solutions; segment profit margin calculation
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||
| Segment profit | 42) | 75) | 57) | 52) | 59) |
| Revenues | 743) | 784) | 741) | 814) | 810) |
| Segment Profitability Ratio | |||||
| Segment profit margin1 | 5.65% | 9.57% | 7.69% | 6.39% | 7.28% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Segment profit margin = 100 × Segment profit ÷ Revenues
= 100 × 42 ÷ 743 = 5.65%
The financial performance of the Contract Sales & Medical Solutions segment from 2018 to 2022 is characterized by revenue volatility and significant fluctuations in operational profitability. While the segment achieved a peak in efficiency in 2021, the subsequent period witnessed a marked contraction in both top-line results and bottom-line margins.
- Revenue Trends
- Revenues remained relatively stable between 2018 and 2019, maintaining levels above US$ 810 million. A notable decline occurred in 2020, with revenues falling to US$ 741 million. Although a partial recovery was observed in 2021 with an increase to US$ 784 million, the trend reversed in 2022, as revenues decreased again to US$ 743 million.
- Segment Profit Performance
- Segment profit exhibited an inconsistent trajectory, starting at US$ 59 million in 2018 and dipping to US$ 52 million in 2019. A period of growth followed, culminating in a five-year peak of US$ 75 million in 2021. This growth was abruptly reversed in 2022, when profit fell to US$ 42 million, representing the lowest profit level in the observed five-year period.
- Profit Margin Analysis
- The segment profit margin experienced a period of expansion between 2019 and 2021, rising from 6.39% to a high of 9.57%. This suggests an increase in operational efficiency or a favorable shift in cost structures during those years. However, this trend shifted sharply in 2022, with the margin compressing to 5.65%, indicating a significant reduction in the segment's ability to convert revenue into profit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Revenues
IQVIA Holdings Inc., revenues by reportable segment
US$ in millions
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Technology & Analytics Solutions | 5,746) | 5,534) | 4,858) | 4,486) | 4,137) |
| Research & Development Solutions | 7,921) | 7,556) | 5,760) | 5,788) | 5,465) |
| Contract Sales & Medical Solutions | 743) | 784) | 741) | 814) | 810) |
| Total | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Total revenues exhibited a sustained upward trajectory over the five-year period from 2018 to 2022, increasing from US$ 10,412 million to US$ 14,410 million. The most significant growth acceleration occurred between 2020 and 2021, during which total revenue increased by approximately 22.1%.
- Technology & Analytics Solutions
- This segment demonstrated consistent year-over-year growth, rising from US$ 4,137 million in 2018 to US$ 5,746 million in 2022. The steady increase suggests a stable expansion in demand for technology-driven services, with no annual declines recorded during the period.
- Research & Development Solutions
- As the primary revenue driver, this segment grew from US$ 5,465 million in 2018 to US$ 7,921 million in 2022. Although growth remained modest through 2020, a substantial surge was observed in 2021, where revenues increased from US$ 5,760 million to US$ 7,556 million, accounting for the majority of the company's overall revenue expansion.
- Contract Sales & Medical Solutions
- This segment remained relatively stagnant and experienced a slight overall contraction, ending 2022 at US$ 743 million compared to US$ 810 million in 2018. The revenue for this segment fluctuated narrowly between US$ 741 million and US$ 814 million, indicating a lack of growth momentum relative to the other business lines.
- Aggregate Revenue Composition
- The overall growth profile is characterized by a increasing concentration in Research & Development and Technology & Analytics Solutions. By 2022, the combined contribution of these two segments represented the vast majority of total revenue, while the proportional contribution of Contract Sales & Medical Solutions diminished over the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Segment profit
IQVIA Holdings Inc., segment profit by reportable segment
US$ in millions
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|
| Technology & Analytics Solutions | 1,550) | 1,458) | 1,216) | 1,101) | 1,023) |
| Research & Development Solutions | 1,695) | 1,476) | 1,048) | 1,141) | 1,128) |
| Contract Sales & Medical Solutions | 42) | 75) | 57) | 52) | 59) |
| Total | 3,287) | 3,009) | 2,321) | 2,294) | 2,210) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Total segment profit exhibited a consistent upward trajectory over the five-year period from 2018 to 2022, increasing from 2,210 million USD to 3,287 million USD. This growth was primarily driven by the expansion of the Technology & Analytics Solutions and Research & Development Solutions segments, which together account for the vast majority of the organization's profitability.
- Technology & Analytics Solutions
- This segment demonstrated steady and uninterrupted growth throughout the analyzed period. Profit increased from 1,023 million USD in 2018 to 1,550 million USD in 2022, representing a compounded growth trend. The progression was linear, with the most significant year-over-year increase occurring between 2020 and 2021.
- Research & Development Solutions
- Profitability within this segment showed more volatility compared to Technology & Analytics. After a slight decline in 2020 to 1,048 million USD, the segment experienced an aggressive acceleration in growth, reaching 1,476 million USD in 2021 and peaking at 1,695 million USD in 2022. By the end of the period, this segment emerged as the largest contributor to total segment profit.
- Contract Sales & Medical Solutions
- This segment provided a marginal and inconsistent contribution to overall profitability. Profits fluctuated between a low of 42 million USD in 2022 and a high of 75 million USD in 2021. The overall trend for this segment was negative, ending the period lower than the 59 million USD reported in 2018.
- Aggregate Profit Trends
- The total profit growth was characterized by a modest increase between 2018 and 2020, followed by a sharp acceleration in 2021 and 2022. The combined growth of the two primary segments effectively neutralized the volatility and decline observed in the Contract Sales & Medical Solutions unit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?